Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Clinical trial NCT06880913 · RECRUITING

Trial details

NCT number: NCT06880913
Sponsor: Peking University People's Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Start date: 2024-11-14
Primary completion: 2026-12-31
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.